We are pleased to announce that Gi-Hoon Nam, CEO of SHIFTBIO, was invited to the ‘2023 Biopharma Open Innovation' as a speaker on September 20th, 2023. The event was held under "Emerging New Modalities in Biopharmaceuticals." At this event, representatives from leading biopharmaceutical companies in Korea convened to share challenges and insights on the drug development industry.
During the primary session, SHIFTBIO, along with LegoChem Biosciences, Prazer Therapeutics, and GC Pharma, participated as speakers and presented the latest trends on the new modalities in drug development. The second part of the event was a networking session to foster potential collaboration and mutual future advancement. SHIFTBIO is committed to consistently giving our utmost effort, and your continuous attention and support towards SHIFTBIO will be greatly appreciated!
We are pleased to announce that Gi-Hoon Nam, CEO of SHIFTBIO, was invited to the ‘2023 Biopharma Open Innovation' as a speaker on September 20th, 2023. The event was held under "Emerging New Modalities in Biopharmaceuticals." At this event, representatives from leading biopharmaceutical companies in Korea convened to share challenges and insights on the drug development industry.
During the primary session, SHIFTBIO, along with LegoChem Biosciences, Prazer Therapeutics, and GC Pharma, participated as speakers and presented the latest trends on the new modalities in drug development. The second part of the event was a networking session to foster potential collaboration and mutual future advancement. SHIFTBIO is committed to consistently giving our utmost effort, and your continuous attention and support towards SHIFTBIO will be greatly appreciated!